focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Tina is still around

Fri, 24th Sep 2021 12:27

* European stock fall

* Wall Street futures lower

* Evergrande fears persist

* Yields march on higher

Sept 24 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

TINA IS STILL AROUND (1127 GMT)

Something tells us that the TINA (there is no alternative)
effect is still ready to fuel a buy-the-dip mentality.

In a research report Barclays analysts highlight that a
material selling in ETFs on risk-off Monday was followed by
significant inflows.

“So once again, the retail ‘army’ is showing animal
spirits,” according to Barclays analysts.

Looking at a broader picture, they say now the main
categories of investors are fully invested, “which means they
are in a position to sell if something goes wrong.”

“But investors also appear to be well hedged, with high skew
and put-call ratios both signalling significant protection in
place,” they add.

They call this positioning “cautiously long.”

(Stefano Rebaudo)

*****

YOU'RE NEVER(GRANDE) GONNA BELIEVE IT (0942 GMT)

The woes of debt-hobbled Evergrande must have slammed the
Chinese property sector shares this week, right?

Well not really!

As you can see below, many stocks are up on the week at the
exception of course of Sinic Holdings which was
suspended from trade on Monday.

Even more surprisingly, Evergrande itself has scored a
modest gain.

Maybe it's just some traders taking punts after the huge
crashes of the last few months - Evergrande is still down more
than 80% this year - but Beijing clearly wants to avoid a
complete implosion, so the question is, is it something to build
on?
Here's the same table year-to-date:

And here's some reading on the sector:

ANALYSIS-Chinese property debt issuers face 'Evergrande
premium' as worries mount

(Marc Jones)

*****

BANK STOCKS? FORGET CHINA, LOOK AT RATES (0935 GMT)

Higher rates expectations are supposed to boost European
bank stocks while China real estate concerns might present a
downside risk to the sector.

The big question is what between these two factors is going
to prevail.

Credit Suisse analysts see limited direct exposure to
China’s troubled Evergrande.

“Data collection from banks’ disclosures, and cross-check
with Bank of International Settlements (BIS) data on banks’
cross-border positions, suggests Mainland China and Hong Kong
lending by European banks is broadly quite limited,” they say.

JP Morgan does not expect meaningful exposure for European
banks, except for HSBC and Standard Chartered.
Its analysis of syndicated loans data available for major
property developers in China suggests “limited involvement.”

Credit Suisse analysts noted that during the 2014-15
slowdown, banks with more emerging markets balance sheet
exposure underperformed the STOXX 600 bank stock index.

Furthermore, episodes where U.S. 10-year rates rise more
than 50bp over 3 months on average “lead to a 10% rise in the
bank stock index.”

“SocGen, ING and Lloyds (all
rated Outperform by the team) have performed best on average
over three months during these rate episodes,” they add.

The chart below shows the STOXX 600 bank index and
U.S. 10-year Treasury yields and their correlation
(on 75-day data).

(Stefano Rebaudo and Anushka Trivedi)

*****

EUROPE'S SHARES SLIDE, BUT STILL SET FOR WEEKLY GAINS (0725
GMT)

European shares are falling amid concerns about the fate of
embattled property developer China Evergrande Group and a sudden
spike in bond yields. But after three days of strong
performance, the STOXX 600 is still set for weekly gains.

The top fallers this morning are sport clothing brands and
retailers Adidas, Puma and JD Sports
after rival Nike reported a Q4 results miss and cut its
FY 2022 sales expectations due to a supply chain crunch brought
in by months-long factory closures in Vietnam.

On a brighter note, shares in Astrazeneca rise
around 3% after the company reported positive results from the
PROpel Phase III trial.

(Joice Alves)

*****

MOVE OVER EVERGRANDE, TIME TO WATCH SOARING BOND YIELDS
(0705 GMT)

World markets remain on edge on Friday as simmering concerns
about the fate of embattled property developer China Evergrande
Group and a sudden spike in bond yields remind investors that
the final quarter of 2021 will be tricky to navigate.

European and U.S. stock futures fluctuated between gains and
losses after U.S. stocks posted their biggest two-day rise since
July.

While a large part of those gains can be attributed to
easing concerns about Evergrande contagion, Thursday's spike in
yields in the global $60 trillion plus government debt markets
raised the prospects of tighter monetary policy sooner than
later.

Long-term U.S. Treasury yields have surged the most in 18
months as traders brought forward expectations for the first Fed
rate hike to the end of 2022 and the Bank of England opened the
door to a 2021 rate increase -- sparking the biggest jump in
two-year UK gilt yields since March 2015.

Yield curves from Australia to Germany bear steepened in
response and the dollar sprung to the top of its 2021 trading
range. While it remains to be seen whether the rise in yields
can be sustained, some signs of weakness can be detected in the
“buy the dip” trade from investors.

Value stocks, a beneficiary of higher yields, outperformed
growth ones on Thursday while FAANG stocks have underperformed
broader markets so far this month. And if investors are hoping
quiet weekend, think again.

Sunday's election in powerhouse European economy Germany
will provide food for thought as Chancellor Angela Merkel steps
down after 16 years in charge.

Her successor will play a new role in shaping domestic and
broader EU policy and have to steer Germany's economy through a
still uncertain post-COVID environment.

Thursday's flash PMIs for September pointed to a sharp
slowdown in economic activity from the previous month from
rising energy prices and difficulty in sourcing parts and
materials, headwinds that are unlikely to abate in the coming
days.

Key developments that should provide more direction to
markets on Friday:

- ECB's Lagarde says many causes of inflation spike
temporary: CNBC

- Nike warns on holiday delays, cuts full-year sales
estimate

- Daimler's Mercedes-Benz to take a 33% stake in
battery cell manufacturer Automotive Cells Company

- Germany's IFO survey for September

- Fed speaker corner: Powell, Clarida

(Saikat Chatterjee)

*****

EUROPE SET FOR WEEKLY GAINS (0635 GMT)

Futures are pointing to a flat open for European bourses but
the STOXX 600 is set for strong weekly gains, with analysts
saying investors bought the dip this week after a sharp Monday
fall, amid uncertainty around the fate of debt-ridden China
Evergrande.

The risk on sentiment was also supported by a rate hike by
the Norwegian central bank and hawkish remarks from the Bank of
England reinforced market expectations that the Federal Reserve
would begin tapering by year end.

Capping the enthusiasm, property developer Evergrande missed
an interest payment deadline on Thursday and has entered a
30-day grace period.

(Joice Alves)

*****

More News
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.